Novartis wins appeal in MSN clash over heart drug generic

Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

MSN scores win in battle with Novartis over heart drug generic

22 October 2024 Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.

Big Pharma

Novartis fails to block first heart-failure generic by Indian rival

13 August 2024 Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Novartis wins appeal in MSN clash over heart drug generic

More on this story

Editor's picks

Editor's picks

More features